Wave Life Sciences reports Q2 2026 results, advances obesity and AATD pipelines

Wave Life Sciences Ltd. announced financial results for the second quarter ended June 30, 2026, along with pipeline updates, on July 30, 2026.

The company said dosing is now underway in the Phase 2a multidose portion of the INLIGHT trial of WVE-007 in participants with BMI between 35 and 50 kg/m2, including those with and without type 2 diabetes.¹ This stage of the trial is enrolling a population with greater adiposity than earlier cohorts, matching the profile expected for later-stage obesity trials.¹ Over a 12-month period, the trial will track body weight, waist circumference, body composition using MRI and DEXA, liver fat via MRI-PDFF, HbA1c, and lipid levels, in participants enrolled across the U.S. and Europe.¹ Wave also said it plans to start Phase 2 trials combining WVE-007 with incretin therapies and testing it for post-incretin maintenance in the second half of 2026.¹

In alpha-1 antitrypsin deficiency, Wave said its request for a meeting with the FDA on a potential accelerated approval pathway for WVE-006 was granted, with the meeting scheduled for the end of summer 2026.¹ For the PNPLA3 liver disease program, the company said a clinical trial application filing for WVE-008 remains on track for the second half of 2026.¹

On finances, Wave reported cash, cash equivalents, and marketable securities of $490.6 million as of June 30, 2026, down from $602.1 million at the end of 2025.¹ The company said this balance is expected to fund operations into the third quarter of 2028.¹ Quarterly revenue was $2.3 million, compared with $8.7 million in the same quarter last year.¹ R&D expenses rose to $51.3 million from $43.5 million a year earlier,¹ and net loss widened to $69.4 million from $50.5 million in the prior-year quarter.¹